October 14, 2025 | Dallas, TX & Aurora, CO — Verily, UCHealth, the University of Colorado Anschutz, and RefinedScience today announced a multi-year strategic collaboration to leverage artificial intelligence and multiomic analytics for advancing translational research, biomarker discovery, and drug development workflows within health systems.
Science Significance
As part of this collaboration, the parties have already tested clinically informed AI models on complex pathology reports in acute myeloid leukemia (AML), achieving over 95 % accuracy and accelerating data extraction 30× faster than manual review. They plan to expand this into multi-modal data (genomics, proteomics, imaging, EHR) across additional high-acuity disease areas to enable smarter drug target validation, mechanistic insights, and precision trial design. .
Regulatory Significance
The work involves integrating large volumes of sensitive patient data, AI model development, and analytics in clinical contexts — all of which require strict data governance, reproducibility, audit trails, validation protocols, and compliance with regulatory standards (e.g. HIPAA, GDPR, FDA guidance on AI/ML medical devices). If models influence clinical decision support or trial stratification, they will need qualification, validation under GxP, and regulatory oversight.
Business Significance
Advertisement
For Verily, the collaboration expands its role from technology provider to co-developer in life sciences, boosting its value proposition in pharma and health systems. For UCHealth/Anschutz/RefinedScience, co-creating AI tools and analytics offers new downstream licensing or service revenue streams. Together, they can accelerate commercial deployment of next-gen insights and attract external biotech/ pharma investment into infrastructure and platform tools.
Patients’ Significance
Patients could benefit via faster, more precise diagnostics, personalized treatment insights, and better trial matching. In conditions like AML or other high-risk diseases, faster insight generation could support timely therapeutic decisions, potentially improving outcomes and reducing diagnostic delays.
Policy Significance
This model underscores the need for policy frameworks on AI in medicine, including model transparency, accountability, validation standards, and cross-institutional data sharing. It may influence how regulators and payers view AI-enabled tools across pharma and health systems, driving development of guidelines on how such collaborations are assessed.
The Verily–UCHealth–Anschutz–RefinedScience collaboration signals a forward leap in merging AI, deep biology, and clinical systems under regulated environments. If executed under stringent validation, auditability, and compliance, it can fuel the next wave of precision-enabled drug discovery and translational research infrastructure — a platform that may become foundational in modern pharma innovation.
Source: Verily press release
